Business ❯ Healthcare

Pharmaceuticals

Drug Development Clinical Trials Market Competition Oncology Weight Loss Drugs Market Trends Biotechnology Drug Pricing Acquisitions Weight Loss

3 ARTICLES

23h ago

Lilly Pulls Ahead in GLP-1 Race as Markets Sharpen Valuation Split

Lilly’s strong U.S. sales, an oral GLP-1 launch and growing hedge-fund holdings have pushed its valuation higher and signaled investor confidence in its commercial momentum.

Stories older than 24h

5 ARTICLES

4d ago

AI-Designed Drug Lowers Proteomic Measures of Biological Age in Phase IIa IPF Trial

12 ARTICLES

last wk.

Abbott Agrees to Pay $385 Million to Settle False‑Claims Case Over Infant Formula

15 ARTICLES

last wk.

Novo Nordisk Becomes 'Novo' as CEO Launches Cultural Reset

3 ARTICLES

2w ago

Lilly Completes Acquisition of AtaiBeckley to Add Rapid‑Acting Depression Pipeline

3 ARTICLES

2w ago

Vaxcyte COO Sells 6,182 Shares After Exercising Deep-Discount Options

9 ARTICLES

3w ago

Capricor Faces Securities Class Action as FDA Extends Review of Duchenne Therapy

3 ARTICLES

3w ago

AbbVie Completes $10.9 Billion Buy of Apogee Therapeutics

8 ARTICLES

3w ago

Lilly to Buy Merida Biosciences for Up to $2.875 Billion

8 ARTICLES

3w ago

McKesson Confirms Cloud Data Theft by Extortion Group

4 ARTICLES

3w ago

Moderna and Merck Report Phase 3 Success for Personalized mRNA Melanoma Vaccine

9 ARTICLES

3w ago

FDA Approves First Broad RAS Inhibitor for Metastatic Pancreatic Cancer

5 ARTICLES

3w ago

Lilly Still Dominates GLP‑1 Market as New Rivals Gain Traction

4 ARTICLES

4w ago

McKesson Agrees to Buy Precision Medicine Group for About $2.25 Billion

21 ARTICLES

4w ago

Moderna and Merck Say Phase 3 Personalized mRNA Melanoma Vaccine Met Key Endpoints

3 ARTICLES

4w ago

Lilly Sues Six U.S. Sellers Over Black‑Market Sales of Unapproved Retatrutide

Pharmaceuticals

Lilly Pulls Ahead in GLP-1 Race as Markets Sharpen Valuation Split

Eli Lilly Breaks Ground on $6.5 Billion Houston Campus to Make Oral GLP-1 Pill

Viking’s VK2735 Shows Durable Weight Loss With Less‑Frequent Dosing

Novo Sets Bold 2030 Targets but Shares Slide After Investors Question Pipeline

Telix to Acquire German Isotope Maker ITM in Up to $2.35 Billion Deal

AI-Designed Drug Lowers Proteomic Measures of Biological Age in Phase IIa IPF Trial

Abbott Agrees to Pay $385 Million to Settle False‑Claims Case Over Infant Formula

Novo Nordisk Becomes 'Novo' as CEO Launches Cultural Reset

Lilly Completes Acquisition of AtaiBeckley to Add Rapid‑Acting Depression Pipeline

Vaxcyte COO Sells 6,182 Shares After Exercising Deep-Discount Options

Never miss stories about

Pharmaceuticals

Capricor Faces Securities Class Action as FDA Extends Review of Duchenne Therapy

AbbVie Completes $10.9 Billion Buy of Apogee Therapeutics

Lilly to Buy Merida Biosciences for Up to $2.875 Billion

McKesson Confirms Cloud Data Theft by Extortion Group

Moderna and Merck Report Phase 3 Success for Personalized mRNA Melanoma Vaccine

FDA Approves First Broad RAS Inhibitor for Metastatic Pancreatic Cancer

Lilly Still Dominates GLP‑1 Market as New Rivals Gain Traction

McKesson Agrees to Buy Precision Medicine Group for About $2.25 Billion

Moderna and Merck Say Phase 3 Personalized mRNA Melanoma Vaccine Met Key Endpoints

Lilly Sues Six U.S. Sellers Over Black‑Market Sales of Unapproved Retatrutide

Never miss stories about

Pharmaceuticals